<div id="readability-page-1"><p>Blalock Williams LLC purchased a new position in shares of  Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 1,855 shares of the company's stock, valued at approximately $954,000. Medpace makes up   0.8% of Blalock Williams LLC's portfolio, making the stock its 29th largest position.</p><ul><li>Can Medpace Stock Keep up this Pace?</li></ul><p>Several other institutional investors have also modified their holdings of the company. Quent Capital LLC purchased a new position in  Medpace in the third quarter valued at $25,000.  Geneos Wealth Management Inc. increased its holdings in shares of  Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock valued at $29,000 after acquiring an additional 37 shares during the last quarter.  Employees Retirement System of Texas acquired a new stake in shares of  Medpace during the 2nd quarter worth about $36,000.  IFP Advisors Inc lifted its stake in  Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company's stock worth $61,000 after purchasing an additional 134 shares during the last quarter.  Finally, Hantz Financial Services Inc. boosted its holdings in  Medpace by 5,075.0% in the second quarter. Hantz Financial Services Inc. now owns 207 shares of the company's stock valued at $65,000 after purchasing an additional 203 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors. </p><h2>Insider Buying and Selling</h2><p>In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the company's stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president owned 27,500 shares of the company's stock, valued at approximately $16,751,625. This represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through the SEC website. Also, CFO Kevin M. Brady sold 3,000 shares of the stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $590.35, for a total transaction of $1,771,050.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares in the company, valued at approximately $3,542,100. The trade was a 33.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 387,925 shares of company stock worth $233,386,647 in the last quarter. Company insiders own  20.30% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of analysts have weighed in on the stock. Wall Street Zen cut shares of Medpace from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 20th. Zacks Research cut shares of Medpace from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday. TD Cowen raised their price objective on Medpace from $356.00 to $462.00 and gave the stock a &#34;sell&#34; rating in a report on Friday, October 24th. Barclays boosted their target price on Medpace from $485.00 to $525.00 and gave the company an &#34;underweight&#34; rating in a report on Monday, December 15th. Finally, Robert W. Baird  set a $613.00 price target on Medpace in a research note on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, Medpace presently has a consensus rating of &#34;Reduce&#34; and an average target price of $491.27.</p><p><b>Get Our Latest Stock Report on MEDP</b></p><h2>Medpace Trading Up 1.3%</h2><p>NASDAQ:MEDP opened at $616.45 on Thursday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $626.26. The stock's 50 day simple moving average is $581.78 and its 200-day simple moving average is $507.20. The firm has a market cap of $17.36 billion, a P/E ratio of 43.11, a PEG ratio of 2.04 and a beta of 1.43. </p><p>Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, beating analysts' consensus estimates of $3.50 by $0.36. The firm had revenue of $659.90 million for the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. Medpace's quarterly revenue was up 23.7% on a year-over-year basis. During the same period last year, the firm posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS.  Research analysts forecast that  Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year. </p><h2>Medpace Company Profile</h2> (Free Report)<p>Medpace Holdings, Inc <span>NASDAQ: MEDP<span></span></span> is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.  </p><p>Medpace's core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.</p><h2>Read More</h2><ul><li>Five stocks we like better than Medpace</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>Executive Order 14330: Trump’s Biggest Yet</li><li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUVEUA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Medpace Right Now?</h2><p>Before you consider Medpace, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medpace wasn't on the list.</p><p>While Medpace currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MEDP

<p>Blalock Williams LLC acquired 1,855 shares of Medpace Holdings, Inc. (NASDAQ:MEDP) valued at approximately $954,000, making it the 29th largest position in their portfolio. Other institutional investors have also increased their stakes in Medpace. Recent insider sales included VP Susan E. Burwig selling 20,000 shares and CFO Kevin M. Brady selling 3,000 shares. Analysts have mixed ratings on Medpace, with a consensus rating of "Reduce" and an average target price of $491.27. Medpace's stock opened at $616.45, with a market cap of $17.36 billion and a P/E ratio of 43.11.</p>

1,855 Shares in Medpace Holdings, Inc. $MEDP Acquired by Blalock Williams LLC